C-C chemokine receptor type 5 (CCR5) (CCR5)

C-C chemokine receptor type 5 (CCR5), often recognized as a primary Macrophage inflammatory protein receptor, is a G protein-coupled receptor (GPCR) predominantly expressed on the surface of immune cells such as T cells, macrophages, and dendritic cells [UniProt]. It serves as a vital mediator of the immune response by facilitating the chemotaxis of leukocytes toward gradients of ligands like MIP-1α (CCL3) and MIP-1β (CCL4) [PubMed]. CCR5 is clinically most significant as the essential co-receptor used by R5-tropic strains of HIV-1 for entering host cells; individuals with a naturally occurring CCR5-Δ32 mutation show strong resistance to HIV infection [NIAID]. This biological importance led to the development of Maraviroc, the first FDA-approved CCR5 antagonist used to manage HIV/AIDS by blocking viral entry [Drugs.com]. Beyond its role in infectious disease, CCR5 is increasingly studied for its involvement in cancer metastasis and chronic inflammatory conditions, where its signaling contributes to disease progression [Nature Reviews Drug Discovery]. Current therapeutic research continues to explore CCR5 inhibition as a strategy for treating various malignancies, autoimmune diseases, and preventing organ transplant rejection.

Other names

Macrophage inflammatory protein 1-alpha receptorMIP-1 receptorCD195CKR5CC-CKR-5CHEBR13IDDM22CMKBR5

CCR5 antagonists function as allosteric inhibitors that bind to the transmembrane cavity of the receptor, inducing a conformational change that prevents the interaction between the viral envelope protein (gp120) and the receptor, thereby blocking HIV-1 entry [StatPearls]. These drugs also competitively or allosterically inhibit the binding of natural chemokine ligands such as MIP-1α and MIP-1β, which prevents downstream G-protein signaling and reduces the recruitment of pro-inflammatory cells to sites of injury or infection [NCBI].